Does the media refer more to PBYI or NMAD?

In the previous week, Puma Biotechnology had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Puma Biotechnology's score of 0.58 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LRMR or NMAD?

Larimar Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 170.06%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.10 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, LRMR or NMAD?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.00 N/A

Is LRMR or NMAD more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Lixte Biotechnology N/A -134.91% -95.61%

Does the media prefer LRMR or NMAD?

In the previous week, Larimar Therapeutics had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Larimar Therapeutics and 1 mentions for Lixte Biotechnology. Larimar Therapeutics' average media sentiment score of 1.80 beat Lixte Biotechnology's score of 0.69 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RZLT or NMAD?

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 100.32%. Given Rezolute's stronger consensus rating and higher possible upside, equities research analysts plainly believe Rezolute is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 2 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, RZLT or NMAD?

Rezolute is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.00 N/A

Is RZLT or NMAD more profitable?

Rezolute's return on equity of -58.82% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Lixte Biotechnology N/A -134.91% -95.61%

Does the media favor RZLT or NMAD?

In the previous week, Rezolute had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Lixte Biotechnology. Rezolute's average media sentiment score of 1.79 beat Lixte Biotechnology's score of 0.69 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NMAD or CABA?

Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 430.57%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has stronger valuation & earnings, NMAD or CABA?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.00 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is NMAD or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Cabaletta Bio N/A -128.27% -95.47%

Does the media prefer NMAD or CABA?

In the previous week, Cabaletta Bio had 9 more articles in the media than Lixte Biotechnology. MarketBeat recorded 10 mentions for Cabaletta Bio and 1 mentions for Lixte Biotechnology. Cabaletta Bio's average media sentiment score of 0.77 beat Lixte Biotechnology's score of 0.69 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KMDA or NMAD?

Kamada currently has a consensus price target of $13.00, indicating a potential upside of 67.53%. Given Kamada's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kamada is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer KMDA or NMAD?

In the previous week, Kamada had 24 more articles in the media than Lixte Biotechnology. MarketBeat recorded 25 mentions for Kamada and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Kamada's score of 0.34 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 4 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lixte Biotechnology (NMAD) Competitors

$3.90 -0.15 (-3.70%)

As of 04:00 PM Eastern

Compare

NMAD vs. PBYI, LRMR, RZLT, CABA, and KMDA

Should you buy Lixte Biotechnology stock or one of its competitors? Lixte Biotechnology's main competitors and comparable companies include Puma Biotechnology (PBYI), Larimar Therapeutics (LRMR), Rezolute (RZLT), Cabaletta Bio (CABA), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lixte Biotechnology compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 7.3% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Puma Biotechnology has a net margin of 11.50% compared to Lixte Biotechnology's net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Puma Biotechnology has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$231.24M	1.97	$31.11M	$0.52	16.96
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

Puma Biotechnology currently has a consensus target price of $6.00, indicating a potential downside of 31.97%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Puma Biotechnology is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Puma Biotechnology has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, Puma Biotechnology had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Puma Biotechnology's score of 0.58 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats Lixte Biotechnology on 12 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

Larimar Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 170.06%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology's return on equity of -134.91% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Lixte Biotechnology	N/A	-134.91%	-95.61%

In the previous week, Larimar Therapeutics had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Larimar Therapeutics and 1 mentions for Lixte Biotechnology. Larimar Therapeutics' average media sentiment score of 1.80 beat Lixte Biotechnology's score of 0.69 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Summary

Larimar Therapeutics beats Lixte Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 100.32%. Given Rezolute's stronger consensus rating and higher possible upside, equities research analysts plainly believe Rezolute is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rezolute has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Rezolute's return on equity of -58.82% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Rezolute is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

In the previous week, Rezolute had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Lixte Biotechnology. Rezolute's average media sentiment score of 1.79 beat Lixte Biotechnology's score of 0.69 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Rezolute beats Lixte Biotechnology on 10 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to Cabaletta Bio?

Lixte Biotechnology (NASDAQ:NMAD) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

5.1% of Lixte Biotechnology shares are owned by institutional investors. 7.3% of Lixte Biotechnology shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cabaletta Bio had 9 more articles in the media than Lixte Biotechnology. MarketBeat recorded 10 mentions for Cabaletta Bio and 1 mentions for Lixte Biotechnology. Cabaletta Bio's average media sentiment score of 0.77 beat Lixte Biotechnology's score of 0.69 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 430.57%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Cabaletta Bio's return on equity of -128.27% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Cabaletta Bio	N/A	-128.27%	-95.47%

Lixte Biotechnology has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, indicating that its share price is 230% more volatile than the broader market.

Summary

Cabaletta Bio beats Lixte Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to Kamada?

Kamada (NASDAQ:KMDA) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Kamada has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.47	$20.20M	$0.38	20.42
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

Kamada has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Kamada currently has a consensus price target of $13.00, indicating a potential upside of 67.53%. Given Kamada's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kamada is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.4% of Kamada shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Lixte Biotechnology's net margin of 0.00%. Kamada's return on equity of 8.37% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Lixte Biotechnology	N/A	-134.91%	-95.61%

In the previous week, Kamada had 24 more articles in the media than Lixte Biotechnology. MarketBeat recorded 25 mentions for Kamada and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.69 beat Kamada's score of 0.34 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	4 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Lixte Biotechnology on 13 of the 15 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMAD vs. The Competition

Export

Metric	Lixte Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$73.99M	$3.78B	$7.00B	$13.02B
Dividend Yield	N/A	3.68%	2.57%	10.42%
P/E Ratio	-3.45	11.60	271.41	25.43
Price / Sales	N/A	1,304.98	604.50	98.25
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	3.71	17.17	11.09	6.51
Net Income	-$6.01M	-$13.18M	$3.45B	$347.22M
7 Day Performance	-48.07%	1.54%	0.74%	1.51%
1 Month Performance	-48.07%	2.99%	2.14%	2.73%
1 Year Performance	8.64%	56.69%	62.99%	21.07%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMAD Lixte Biotechnology	0.0632 of 5 stars	$3.90 -3.7%	N/A	+109.2%	$73.99M	N/A	N/A	4
PBYI Puma Biotechnology	0.9093 of 5 stars	$8.70 -0.1%	$6.00 -31.0%	+54.1%	$448.32M	$231.24M	16.70	200	Analyst Upgrade
LRMR Larimar Therapeutics	4.0588 of 5 stars	$4.31 +0.8%	$12.57 +192.0%	+8.7%	$447.20M	N/A	N/A	30	Positive News
RZLT Rezolute	2.7986 of 5 stars	$4.62 +0.3%	$9.38 +103.1%	-29.2%	$444.38M	N/A	N/A	40	Positive News
CABA Cabaletta Bio	2.4475 of 5 stars	$2.72 +0.2%	$15.33 +464.8%	+60.8%	$443.01M	N/A	N/A	50	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMAD) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (NMAD) Competitors

NMAD vs. PBYI, LRMR, RZLT, CABA, and KMDA

How does Lixte Biotechnology compare to Puma Biotechnology?

Summary

How does Lixte Biotechnology compare to Larimar Therapeutics?

Summary

How does Lixte Biotechnology compare to Rezolute?

Summary

How does Lixte Biotechnology compare to Cabaletta Bio?

Summary

How does Lixte Biotechnology compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (NMAD) Competitors

NMAD vs. PBYI, LRMR, RZLT, CABA, and KMDA

How does Lixte Biotechnology compare to Puma Biotechnology?

Do insiders and institutionals believe in PBYI or NMAD?

Is PBYI or NMAD more profitable?

Which has stronger earnings & valuation, PBYI or NMAD?

Do analysts prefer PBYI or NMAD?

Which has more risk & volatility, PBYI or NMAD?

Does the media refer more to PBYI or NMAD?

Summary

How does Lixte Biotechnology compare to Larimar Therapeutics?

Do institutionals and insiders have more ownership in LRMR or NMAD?

Which has higher valuation and earnings, LRMR or NMAD?

Do analysts prefer LRMR or NMAD?

Is LRMR or NMAD more profitable?

Does the media prefer LRMR or NMAD?

Which has more risk & volatility, LRMR or NMAD?

Summary

How does Lixte Biotechnology compare to Rezolute?

Do analysts prefer RZLT or NMAD?

Which has more risk and volatility, RZLT or NMAD?

Is RZLT or NMAD more profitable?

Which has stronger valuation & earnings, RZLT or NMAD?

Does the media favor RZLT or NMAD?

Do insiders & institutionals have more ownership in RZLT or NMAD?

Summary

How does Lixte Biotechnology compare to Cabaletta Bio?

Do insiders and institutionals have more ownership in NMAD or CABA?

Does the media prefer NMAD or CABA?

Which has stronger valuation & earnings, NMAD or CABA?

Do analysts prefer NMAD or CABA?

Is NMAD or CABA more profitable?

Which has more risk & volatility, NMAD or CABA?

Summary

How does Lixte Biotechnology compare to Kamada?

Which has better valuation & earnings, KMDA or NMAD?

Which has more risk and volatility, KMDA or NMAD?

Do analysts rate KMDA or NMAD?

Do institutionals and insiders hold more shares of KMDA or NMAD?

Is KMDA or NMAD more profitable?

Does the media prefer KMDA or NMAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools